Clinical trials
Multiple Sclerosis (MS) Primary Progressive clinical trials
Below are recruiting multiple sclerosis (ms) primary progressive clinical trials, each written for real people, not researchers. We’re tracking 57 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT01703429Recruiting
Alternative care program for people with multiple sclerosis
This study looks at how a complementary or alternative care approach affects people living with multiple sclerosis. It may help to understand whether this type of program improves symptoms or quality of life over time.
Kenmore, WashingtonAges 18–100 - NCT05834855RecruitingPhase 3
Rituximab versus ocrelizumab for relapsing multiple sclerosis
This Phase 3 trial compares two similar immune therapies—rituximab and ocrelizumab—to see if rituximab works about as well for relapsing multiple sclerosis. It may help you and researchers understand which option is equally effective and safe for preventing relapses and disease activity.
AmsterdamAges 18 years+ - NCT05961644RecruitingPhase 2/Phase 3
Cladribine vs placebo for non-active progressive multiple sclerosis
This trial tests whether cladribine (vs an inactive placebo pill) can slow disability worsening in people with a non-active, progressive form of multiple sclerosis. It may help by reducing the immune activity that can drive ongoing nerve damage, even without recent relapses.
Warsaw, Masovian VoivodeshipAges 30–65 - NCT05740722RecruitingPhase 2
Nicotinamide riboside for progressive multiple sclerosis
This Phase 2 trial studies whether a vitamin-like supplement called nicotinamide riboside can slow or improve disability in progressive multiple sclerosis. It may help people whose symptoms have been steadily getting worse over the last 2 years.
BergenAges 18–65 - NCT05204459Recruiting
MRI and eye-scan study for MS and related conditions
This trial uses brain MRI and eye imaging tests to study research markers in people with multiple sclerosis (MS) and related neurologic conditions. It may help researchers better understand these diseases and how they change over time.
Los Angeles, CaliforniaAges 18 years+ - NCT07840326RecruitingPhase 2
Study of SUN-627 for progressive multiple sclerosis
This study tests an experimental medicine called SUN-627 for people with progressive multiple sclerosis (MS) that is not currently flaring up. The goal is to see if it can slow down worsening disability without causing serious side effects.
Atlanta, GeorgiaAges 18–70 - NCT06461481Recruiting
Follow-up strategies for de-escalating multiple sclerosis treatment
This study tests different ways of monitoring people with relapsing-remitting MS who are reducing or stopping their medication. It aims to find the safest follow-up approach and may help guide future treatment decisions for those with stable disease.
DüsseldorfAges 18 years+ - NCT05811013Recruiting
Static magnetic brain stimulation for progressive multiple sclerosis
This trial studies whether a noninvasive brain stimulation approach using a static magnetic field can help people with progressive multiple sclerosis. It aims to improve progressive nerve function while keeping other treatments stable.
Pozzilli, IserniaAges 18–65 - NCT07587125RecruitingPhase 1
CAR-T Cell Therapy for Progressive Multiple Sclerosis
This trial tests a new cell therapy called S103 for people with MS that isn't responding well to standard treatments. The therapy involves modifying immune cells in the lab and putting them back into your body to help control the disease.
Xi'an, ShaanxiAges 18–75 - NCT05177523Recruiting
MRI study of nerve damage and repair in multiple sclerosis
This trial uses MRI scans to better understand how nerve fibers are damaged and repaired in people with multiple sclerosis. It may help researchers connect scan findings to disease activity and progression.
BaselAges 18–80 - NCT07503873RecruitingPhase 2
Study of ublituximab injection for multiple sclerosis
This trial tests a new way to give the drug ublituximab (an injection under the skin) to people with relapsing multiple sclerosis. It compares different injection sites and a special auto-injector device to see how the body absorbs the drug and if it's safe.
BihaćAges 18–65 - NCT07477639RecruitingPhase 1/Phase 2
Testing TRX319 for worsening multiple sclerosis
This trial tests a new treatment called TRX319 for people with progressive multiple sclerosis (MS) that has been getting worse. The study wants to see if this treatment can help slow down disability progression.
La Jolla, CaliforniaAges 18–65 - NCT07426991Recruiting
Multiple sclerosis, thinking, sleep, and tiredness study
This study looks at how multiple sclerosis (MS) affects your thinking, sleep, and tiredness. It compares people with MS who have at least mild fatigue to people without MS who also have sleep problems, to understand these issues better.
DüsseldorfAges 18–79 - NCT07392879Recruiting
Virtual nature walks for depression in MS
This study tests whether virtual reality nature walks can help improve depression in people with progressive multiple sclerosis. You will use a VR headset at home to watch calming nature scenes, and researchers will see how it affects your mood.
Ann Arbor, MichiganAges 18 years+ - NCT06845722Recruiting
Balance and cognitive training for multiple sclerosis
This trial tests whether combining balance exercises with brain-training activities can help improve walking and thinking in people with multiple sclerosis. It is for people aged 40–55 who have mild cognitive problems and balance issues.
LahoreAges 40–55 - NCT07355387Recruiting
Home-based balance training for multiple sclerosis
This study tests a 12-week home-based balance training program for people with multiple sclerosis. Sessions are done online with a helper present, and the goal is to improve walking and reduce fall risk.
Chicago, IllinoisAges 40–90 - NCT07325292RecruitingPhase 3
Frexalimab injection vs IV for multiple sclerosis
This study tests if a new injection (frexalimab) works as well as the IV version for people with relapsing or certain types of secondary progressive multiple sclerosis. It could offer a more convenient way to receive this treatment at home.
Cullman, AlabamaAges 18–60 - NCT07299019RecruitingPhase 3
Study of orelabrutinib for secondary progressive MS
This study tests an oral medication called orelabrutinib for people whose multiple sclerosis has changed from relapsing-remitting to secondary progressive. The goal is to see if it can slow down disability worsening that happens even without relapses.
Phoenix, ArizonaAges 18–60 - NCT07303790RecruitingEarly Phase 1
Study of GC012F for people with multiple sclerosis
This early phase trial tests a new treatment called GC012F for people with multiple sclerosis. It aims to see how safe and tolerable it is, and may offer a new option for those whose current treatments are not working well enough.
Hubei, HubeiAges 18 years+ - NCT07222618Recruiting
Selfie videos to measure function in MS
This trial asks people with MS to record short 'selfie' videos of themselves doing everyday tasks, like walking or getting dressed. The goal is to find a better, more personal way to measure how MS affects daily function.
San Francisco, CaliforniaAges 18 years+ - NCT07178431RecruitingPhase 1/Phase 2
CAR T-cell therapy for worsening multiple sclerosis
This trial tests a new treatment called MB-CART2019.1, which uses your own immune cells to fight multiple sclerosis. It is for people with progressive or worsening MS who have not responded well to other treatments.
BerlinAges 18–55 - NCT07085676RecruitingPhase 1
CAR-T cell therapy for autoimmune diseases that resist treatment
This study tests a new cell therapy called CAR-T (using your own immune cells) for people with severe autoimmune diseases like lupus, scleroderma, or myositis that have not improved with standard treatments. The goal is to see if it can safely reduce disease activity.
JerusalemAges 18–80 - NCT07067463RecruitingPhase 3
Testing orelabrutinib for primary progressive MS
This trial tests a daily pill called orelabrutinib to see if it can slow disability progression in people with primary progressive multiple sclerosis (PPMS). It may be an option for patients whose symptoms have been getting worse over the past two years.
Pheonix, ArizonaAges 18–60 - NCT07011914Recruiting
MS care study for young adults
This study looks at how to improve care for young adults with relapsing-remitting MS. It focuses on people who are Black, Hispanic, or have limited income.
Birmingham, AlabamaAges 18 years+
Hear when a new Multiple Sclerosis (MS) Primary Progressive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for multiple sclerosis (ms) primary progressive?
- Yes. Clin2 currently lists 57 recruiting multiple sclerosis (ms) primary progressive studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a multiple sclerosis (ms) primary progressive trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a multiple sclerosis (ms) primary progressive trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Multiple Sclerosis, Primary Progressive
- Multiple Sclerosis, Secondary Progressive
- Progressive Multiple Sclerosis
- Multiple Sclerosis (MS) Secondary Progressive
- Multiple Sclerosis, Chronic Progressive
- Multiple Sclerosis, Relapsing-Remitting
- Primary Progressive Aphasia
- Multiple Sclerosis (MS) - Relapsing-remitting
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.